Introducing Health Answers by Pfizer

Health Answers by Pfizer is a new consumer digital experience powered by generative artificial intelligence that allows you to ask your biggest and smallest health and wellness questions - anytime, anywhere - and receive real-time, relevant responses and next steps.

Pfizer's Award-winning Podcast, Science Will Win, Returns for Season 4

The new season of Science Will Win takes you on a journey to discover how artificial intelligence is helping to unlock new frontiers in drug discovery and development.

Accelerating Breakthroughs in Genitourinary Cancers

Focused on addressing these unmet needs across all disease stages of Genitourinary cancers, at Pfizer, we aspire to accelerate breakthroughs that help people with these difficult-to-treat cancers live better and longer lives.

Know Your Prostate Plan

A Prostate Cancer diagnosis can be overwhelming and emotional. Dan, who has been living with the disease since 2008, shares an important reminder for those facing a diagnosis. Find more resources at Know Your Prostate Plan.

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.

Pfizer News

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 24, 2025
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
February 13, 2025
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 12, 2025
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
February 10, 2025
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
February 04, 2025
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
February 03, 2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
January 28, 2025
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 25, 2025
Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-NaÏve, High-Risk Non-Muscle Invasive Bladder Cancer
January 10, 2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 06, 2025
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
December 20, 2024
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
December 19, 2024
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
December 17, 2024
Pfizer Declares First-Quarter 2025 Dividend
December 12, 2024
Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
December 12, 2024
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
December 10, 2024
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
December 10, 2024
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
December 05, 2024

Click here to view all Pfizer News stories.

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community